Serious adverse events · children aged 5 to 11 years
1 finding from 1 review
Serious adverse events · children aged 5 to 11 years
1 finding from 1 review
Serious adverse events · children aged 5 to 11 years
1 finding from 1 review
Serious adverse events · children aged 12 to 18 years
1 finding from 1 review
Serious adverse events · children aged 12 to 18 years
1 finding from 1 review
Serious adverse events · children aged 12 to 18 years
1 finding from 1 review
Intervention not reported
Serious adverse events Measured by: proportion of serious adverse events (total) Average study duration (range): not stated · children and adolescents aged 18 years and under diagnosed with ADHD
It is very uncertain whether the intervention changes serious adverse events Measured by: proportion of serious adverse… (very low certainty).
1 finding from 1 review
Participants with adverse events: 1 or more serious adverse events regardless of type of storage of the vaccine Clinical or laboratory criteria · healthy older adults aged ≥ 60 years
Live zoster vaccine showed no clear difference in participants with adverse events: 1 or more serious adverse events… compared with placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events Measured by: proportion of any serious adverse events Average study duration (range): 4.7 months (14 days to 21 months) · children and adolescents aged 18 years and under diagnosed with ADHD
1 finding from 1 review
Intervention not reported
Non‐serious adverse events Measured by: proportion of any non‐serious adverse events Average study duration (range): 5.99 months (1 day to 41 months) · children and adolescents aged 18 years and under diagnosed with ADHD
1 finding from 1 review
Intervention not reported
Withdrawal of methylphenidate due to non‐serious adverse events Measured by: proportion of participants withdrawn from treatment Average study duration (range): 5.60 months (0.6 months to 41 months) · children and adolescents aged 18 years and under diagnosed with ADHD
1 finding from 1 review
Intervention not reported
Withdrawal of methylphenidate due to serious adverse events (non‐comparative cohort studies) Measured by: proportion of participants withdrawn from treatment Average study duration (range): 7.9 months (1 month to 37 months) · children and adolescents aged 18 years and under diagnosed with ADHD
1 finding from 1 review
Serious adverse events, defined as any medical event at any dose that results in death, is life‐threatening, requires hospitalisation (or prolongation of existing hospitalisation) or results in permanent damage or disability (FDA 2016) · children with acute postoperative pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events, defined as any medical event at any dose that results in death, is life‐threatening, requires hospitalisation (or prolongation of existing hospitalisation) or results in permanent damage or disability (FDA 2016) · children with acute postoperative pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events, defined as any medical event at any dose that results in death, is life‐threatening, requires hospitalisation (or prolongation of existing hospitalisation) or results in permanent damage or disability (FDA 2016) · children with acute postoperative pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events, defined as any medical event at any dose that results in death, is life‐threatening, requires hospitalisation (or prolongation of existing hospitalisation) or results in permanent damage or disability (FDA 2016) · children with acute postoperative pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse events (serious adverse events) · children (aged 6 to 11 years) being overweight or obese
The intervention showed no clear difference in adverse events (serious adverse events) (low certainty).
1 finding from 1 review
Serious adverse events · aged 18 years and older undergoing elective surgery at any surgical site
1 finding from 1 review
Serious adverse events · aged 18 years and older undergoing elective surgery at any surgical site
1 finding from 1 review
Serious adverse events · patients aged 0 to 18 years with a diagnosis of functional constipation
PEG showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review